Signia Therapeutics to be present at the Options for the Control of Influenza X Conference

August 20, 2019

Very pleased to announce that Dr. Andrés Pizzorno – Signia Therapeutics’ cofounder and Project Manager – has been invited by the Scientific Committee of the Options for the Control of Influenza X Conference, to be held in Singapore from August 28 to September 1 2019, to give a presentation on “Potential host-targeted therapies for influenza”.

The presentation – on Friday August 30 at 10.30 am – will showcase an update of the current clinical trial landscape in the field and a discussion on the future research directions in order to consolidate the host-targeted anti-influenza agents as an important contribution to our limited therapeutic arsenal, not only as putative standalone therapies but also with special focus on their combinatory potential with current classic virus-targeted inhibitors.

The Options X Conference is the premier global meeting focused on influenza, targeting more than 1,500 participants from across the globe. Visit the ISIRV Options X website ( for detailed information.


Leave a comment

Signia - Copyright 2021. All right reserved.